Report Explores the Hidradenitis Suppurativa Market Latest Trends and Insights by 2025

Hidradenitis suppurativa is a dermatological disease that affects areas of apocrine sweat glands such as buttocks, area under the breast, under the arms, inner the thighs. It is also known as acne inversa. The disease is characterized by development of follicular occlusions that lead to progressive scarring. Early symptoms of hidradenitis suppurativa include erythema and local hidradenitis, which become painful in later stages. Hidradenitis suppurativa arises as a result of hormonal imbalance, friction from clothing, and sweating.

According to an article published in Current Dermatology Reports in 2014; smoking, obesity, and genetic factors are also responsible for causing the disease. The disease is more prevalent in women as compared to men, with a ratio of 3:1. Globally, the disease affects around 1% of the population. The disease is uncommon but not rare. It can occur at any age, but it is most common at the age of 20–30 years.

Based on treatment, the global hidradenitis suppurativa market has been segmented into medications, laser treatment, surgery, and others. The medications segment has been sub-segmented into biologics, antibiotics, hormonal therapy, immunosuppressive drugs, zinc supplements, retinoids, pain medication, and others. Currently, only one FDA-approved therapeutic drug i.e. adalimumab (Humira) is available for treatment of hidradenitis suppurativa. Several antibiotics, hormone therapy, and corticosteroids are prescribed off-label. Treatment of hidradenitis suppurativa still remains a challenge for scientists worldwide.

Obtain Report Details @ https://www.transparencymarketresearch.com/hidradenitis-suppurativa-market.html

Surgical removal is also a preferred mode of treatment, but the disease may relapse in other areas. Research to develop drugs for the treatment of hidradenitis suppurativa is currently in progress. As of 2017, certain drugs are under clinical development such as brilacidin, CJM 112, and xilonix. Increase in the incidence of chronic inflammatory skin diseases, the large number of ongoing clinical trials, and introduction to new treatment options are factors likely to boost the hidradenitis suppurativa market during the forecast period.

However, a weak pipeline has questioned growth of the market for hidradenitis suppurativa, as most of these trials are in phase II, indicating lesser chances of approval. This factor is projected to restrain the hidradenitis suppurativa market in the near future. In addition, high cost of therapy and associated side-effects are estimated to restrain the hidradenitis suppurativa market during the forecast period.

Based on skin conditions, the hidradenitis suppurativa market has been divided into pimples, boils, deep-acne, folliculitis, and others. The folliculitis segment has been sub-segmented into hot tub folliculitis (pseudomonas folliculitis), bacterial folliculitis, pityrosporum folliculitis, barber's itch (pseudofolliculitis barbae), and others. The deep-acne segment has been further divided into blackheads, cysts, and others. The boils segment has been sub-divided into pilondial cyst, carbuncle, cystic acne, and others.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=31538

In terms of geography, the global hidradenitis suppurativa market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the global hidradenitis suppurativa market, followed by Europe. Growth of the market in North America is attributable to increase in the number of inflammatory skin conditions and the large number of ongoing clinical trials. Asia Pacific is an emerging market for hidradenitis suppurativa, due to increase in the prevalence of hidradenitis suppurativa in this region.

Developing health care infrastructure and rising government expenditure on the health care industry are factors projected to boost the hidradenitis suppurativa market in Asia Pacific during the forecast period. However, factors such as low awareness among patients, high cost of therapy, and limited access to health care facilities restrain the hidradenitis suppurativa market in regions such as Middle East & Africa and Latin America.

Major players operating in the global hidradenitis suppurativa market include AbbVie Inc., AstraZeneca, Johnson & Johnson, Merck & Co., Inc., Allergan, Pfizer Inc., and GlaxoSmithKline plc.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=31538<ype=S

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.